• New Chairman to Help Speed Products to Market
    L-R Emma Nolan, Dr Marco Giardiello, Dr Lee Tatham, Antony Odell, Professor Steve Rannard and Professor Andrew Owen

News & Views

New Chairman to Help Speed Products to Market

Aug 19 2019

Tandem Nano Ltd, a University of Liverpool spin-out has appointed Antony Odell as Executive Chairman to accelerate the commercialisation of its proprietary technology to reformulate poorly soluble pharmaceuticals and chemicals. Antony has a significant track record in building successful life science businesses from early to late stage. Most recently Antony was CEO at Tissue Regenix Group plc which he led from laboratory proof of concept work to an Alternative Investment Market (AIM) listed business with significant overseas operations.

The University technology, which has been licensed into Tandem, has significant implications for optimisation of product manufacture across a broad range of market sectors from new therapy generation to novel agrochemical formulations, providing partners with tailored nanoparticles of insoluble materials. It is a result of collaboration between the research groups of Professor Andrew Owen, Department of Molecular and Clinical Pharmacology and Professor Steve Rannard, Department of Chemistry. Both Andrew and Steve are directors of the company.

Antony Odell said: “I’m delighted that Tandem has made this important first step in the commercialisation of its proprietary SDN technology which already has a significant track record of success in solving the problems of poorly soluble actives. The team at the University has developed several key commercial relationships that can now be developed further within the new company in a variety of sectors some of which have significant impact for Tandem’s strong corporate social responsibility ethic.”

Professor Andrew Owen, Academic Founder, said: “The spin-out of Tandem Nano Ltd is a resounding endorsement of the University’s cross-faculty activity that has seen new medicines transition from concept through preclinical selection, regulatory approval and first-in-human evaluation. The team will continue to drive development and understanding of new modalities to bring novel therapeutic options to patients that need them across the globe.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events